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Study Objectives: Because of associated abnormalities affecting connective tissue in various organs including airways, hypermobility syndrome has 
been associated with high risk for the development sleep apnea. Ehlers-Danlos syndrome (EDS) and Marfan syndrome (MFS) represent the most common 
hypermobility syndromes; therefore, the purpose of this review was to examine the prevalence of obstructive sleep apnea (OSA) in these populations.
Methods: All publications and poster presentations written in English found through August 2018 that describe the prevalence of sleep apnea among people 
with EDS or MFS were included.
Results: A total of 13 studies were identified, 7 for EDS and 6 for MFS. A combined random prevalence rate of OSA across both populations was 48.9% 
(95% confidence interval 38.3–59.6), with a slightly higher rate of 59.7% (39.7–77.0) for MFS versus 39.4% (28.8–51.1) for EDS. However, a high degree of 
heterogeneity across studies was found in both groups (EDS group: Q = 28.6 and I 2 = 79.0; MFS group: Q = 37.1 and I 2 = 86.5). When directly compared 
to the general population, patients with EDS/MFS were on average six times more likely (odds ratio 6.28 [95% confidence interval 3.31–11.93], P < 0.001, 
Z = 5.61) to have a diagnosis of OSA.
Conclusions: OSA is a previously underestimated EDS/MFS-related complication. The high prevalence of OSA might be the result of bony and soft-tissue 
abnormalities associated with these hypermobility syndromes. Untreated OSA is thought to worsen cardiovascular complications especially among those with 
MFS. Further research is needed to better delineate whether the prevalence of OSA is moderated by factors such as sex, body mass index, bony structure, 
and disorder subtype.
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INTRODUCTION
Hypermobility syndrome is characterized by joint hypermo-
bility, usually with the involvement of organs in the body. 
It is usually a genetic or inheritable disease transmitted 
through an autosomal dominant or recessive gene. Hyper-
mobility syndrome includes several specific disorders af-
fecting different types of collagen in the body, including 
Ehlers-Danlos syndrome (EDS), Marfan syndrome (MFS), 
osteogenesis imperfecta (OI), and other rare syndromes 
(eg, pseudoxanthoma elasticum, cutis laxa syndrome, ec-
topia lentis syndrome, Weill-Marchesani syndrome, and 
Shprintzen-Goldberg syndrome). In addition, hypermobility 
syndrome can occur in people with chromosomal abnormali-
ties with high OSA risk (eg, Down syndrome1) or metabolic 
diseases (eg, homocystinuria and hyperlysinemia). Joint 
pain, dislocation and recurrent injuries, dizziness, exces-
sive daytime sleepiness, and fatigue can be associated with 
hypermobility syndrome. The nine-point Beighton scale is 
used to screen for suspected cases of hypermobility.2 People 
with EDS are at potentially increased risk for OSA due to 
cartilaginous defects, chest deformities, scoliosis, dilated 
aorta causing tracheal compression, and vocal cord abnor-
malities.3 EDS affects 1.5 million people worldwide, with an 
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overall prevalence of 1 in 5,000 births but affecting more 
females than males.4 There are 13 different subtypes.5 MFS 
affects collagen as well, but with patients usually present-
ing as tall, and with long and slender fingers and toes. The 
prevalence of the disorder is thought to be between 6.5 to 20 
per 100,000.6 Although most MFS cases are due to a muta-
tion of the fibrillin-1 gene on chromosome 15q21, a small 
number (less than 10%) lack this mutation. Revised Ghent 
criteria are usually used to diagnose MFS.7 Tall and thin stat-
ure, scoliosis or kyphosis, high arched plate, and mandibular 
retrognathia are usually causes for increased risk of OSA.
Although there are multiple collagenic diseases that 
present with joint hypermobility, research examining OSA 
prevalence has focused on EDS and MFS. Thus, due to this 
limitation, the current systematic review focuses on these 
two types of hypermobility syndrome. Because prevalence 
of OSA varied among studies, our purpose is to evaluate 
the prevalence of OSA among both EDS and MFS and ex-
amining moderators possibly affecting the prevalence; in 
addition, examining difference among common subtypes 
of EDS. It is of importance that OSA be diagnosed and ef-
fectively treat the disorder given its suggestive association 
with worsening of cardiovascular conditions (ie, abdominal 
aneurysm enlargement).
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METHODS
Study Selection and Data Extraction
A literature review using PubMed, Google Scholar, PLOS, and 
Ovid was conducted through August 2018. Published articles 
and/or posters written in English were identified by searching 
for “Ehlers-Danlos syndrome” or “Marfan syndrome” crossed 
by “obstructive sleep apnea,” “apnea,” or “polysomnography.” 
Studies using both in-laboratory and in-home sleep studies 
were included. However, those based on questionnaires ob-
tained from individuals were excluded because there is a lack 
of reliability in diagnosing OSA through self-reports.8,9
Statistical Analysis
Data were analyzed using the Comprehensive Meta-analysis 
version 2 program to estimate the prevalence of OSA in both 
EDS and MFS. To quantify the amount of dispersion between 
studies, both Cochran Q and I 2 are reported, with 25%, 50%, 
and 75% representing small, moderate, and high levels of het-
erogeneity, respectively, for I 2. In addition, although the mod-
est number of studies does not allow for formal examination of 
moderators that might affect prevalence, study characteristics 
such as sex, age, type of EDS, body mass index (BMI), and 
country where the study was conducted, in addition to preva-
lence, were tabled whenever possible.
RESULTS
Study Extraction
Nine studies were found to assess the prevalence of OSA in pa-
tients with EDS,8,10–17 whereas 13 studies were found for patients 
with MFS. Among the EDS studies, four were posters, three of 
which had overlapping subjects as confirmed by contacting the 
study authors. Accordingly, the study with the greater sample 
was included.10–12 Two other publications used self-reports to 
assess OSA and were thus eliminated.8,12 Finally, unpublished 
data were available by Gaisl and colleagues; thus, a total of 
seven EDS studies (four published articles, two posters, and 
one unpublished data set) representing 875 individuals were in-
cluded in the final analysis10,11,13–17 (Table 1). In the MFS group, 
7 of 13 identified studies were excluded for the following rea-
sons: being a case report,18–20 being part of a larger study,21,22 
or reporting on only individuals with severe OSA for surgery 
and thus representing a significant selection bias.23,24 Thus, the 
MFS sample included the remaining 6 studies, representing a 
total of 282 individuals with MFS25–30 (Table 2).
OSA Prevalence
The prevalence of OSA among people with EDS was 39.4% 
(95% confidence interval [CI] 28.8–51.1, P = .08). In contrast, 
the prevalence rate among those with MFS was 59.7% (39.7–
77.0, P = 0.94). In the EDS group, Q = 28.6 and I 2 = 79.0, 
compared to the MFS group, where Q = 37.1 and I 2 = 86.5 sug-
gesting high heterogeneity rate in both groups. The combined 
13 studies’ prevalence rate was 48.9% (95% CI 38.3–59.6), 
Q = 82.4 and I 2 = 85.4 (Figure 1 and Figure 2).
Age Group and OSA Prevalence
To examine whether prevalence varies among children and 
adults, separate analyses were conducted for each age group. In 
the EDS group, one study included both children and adults,14 
whereas two others reported mean ages but failed to specify age 
range and were thus excluded.10,13 Thus, two studies included 
children totaling 89 children16,17 and one study included 100 
adults.15 There was no observable difference in OSA in children 
Table 1—EDS and OSA.
Study Country (year) Study Population OSA Study Type Referral Source Age (years) Sex (%F) BMI (kg/m
2) AHI (events/h) HST/PSG
Babcock et al. United States (2018)
596 children and 
adults (100% 
hypermobility)
46.48% had SDB 
(HST or PSG), 
32.21% OSA, and 
9.90% UARS
Retrospective 
(2016–2017) Neurology clinic
Mean ± SD 
(range) 36 ± 12.6 
(9–71)
90% Unknown Unknown HST & PSG
Domany et al. United States (2018)
65 children (100% 
hypermobility) 26% OSA
Retrospective 
(2009–2017)
Sleep clinic with 
sleep complaint
Mean ± SD 
13.15 ± 3.9 67.7%
Median (range) 
21.06 (17.9–4.4) Unknown PSG
Gaisl et al. Switzerland (2017)
100 adults (46% 
hypermobile, 35% 
classical and 19% 
other)
32% OSA Prospective
EDS database 
and community 
random sample 
(comparison 
group)
Mean ± SD 
39.9 ± 12.8 82%
Mean ± SD 
24.4 ± 5.6
Median (range) 
2.9 (1.3–7.6) HST
Gaisl et al.* Switzerland 29 adults 27.6% OSA Prospective Community 79.6% Unknown Unknown Unknown
Guilleminault 
et al. France (2013)
34 consecutive 
patients, children 
and adults
100% OSA Retrospective Sleep clinic with sleep complaint Range 7–52 55.9%
Mean ± SD 
23.3 ± 2.1
Median (range) 
14.21 (5.1–38) PSG
Schultz et al. United States (2017)
27 consecutive 
patients with 
hypermobility, 
children and 
adults
70% OSA Retrospective Sleep clinic Mean ± SD 33.1 ± 16 76%
Mean ± SD 
25.3 ± 5.8
Mean ± SD 
11.6 ± 11.5 PSG
Stoberl et al. Switzerland (2017)
24 children 
(AHI > 1 event/h)
42% (compared 
to 13%) Prospective Community Range 6–18 Unknown Unknown Median 0.77 HST
* = unpublished study. AHI = apnea-hypopnea index, BMI = body mass index, EDS = Ehlers-Danlos syndrome, HST = home sleep test (in-
home), OSA = obstructive sleep apnea (AHI at least 1 event/h in children and adolescents and more than 5 events/h in those older than 18 years), 
PSG = polysomnography (in-laboratory), SD = standard deviation, SDB = sleep-disordered breathing (includes primary snoring, UARS, and OSA), 
UARS = upper airway resistance syndrome.
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(prevalence ranging from 26% to 42%; weighted average rate was 
32.1% [95% CI 19.1–48.8; P = .04])16,17 versus adults (weighted 
average prevalence of 31% [23.7–39.5; P < .001]).15 In the MFS 
group, only one study included both children and adults (using 
an apnea-hypopnea index [AHI] cutoff of 5 events/h) but re-
ported subgroups of child patients with OSA using different AHI 
cutoffs (other studies used AHI > 1 event/h in children and > 5 
events/h in adults).30 Thus, this study with a modest sample was 
divided into children in whom OSA was diagnosed using an 
AHI cutoff > 1 event/h (n = 7; OSA was 57.1%) and adults using 
AHI cutoff > 5 events/h (n = 18; OSA was 72.22%). Among the 
two child studies (n = 27), OSA prevalence was 72.3% (95% CI 
Table 2—MFS and OSA.
Authors Country (year) Study Population SDB Study Type Referral Source Age (years) Sex (%F) BMI (kg/m
2) AHI (events/h) HST/PSG
Cistulli et al. Australia(2000)
15 consecutive 
adults 86.67% Prospective Community
Mean ± SD
34.8 ± 13.2
60% Unknown Mean ± SD19 ± 15 PSG
Cistulli et al. Australia(1993) 25 adults 64% 
Prospective, case 
control Community
Mean ± SD
31.9 ± 2.8
52% Unknown Mean ± SD13.76 ± 3 PSG
Kohler et al. Switzerland(2009)
61 adults; 26 
in comparison 
group
32.8% (mild 
14.75%, mod/
severe 18.03%)
Prospective Community Mean ± SD38.3 ± 12.9
60.66% 25.1 ± 5.9 Median (range)5.5 (0.9–13.9) HST
Paoloni et al. Italy (2018) 20 children 80% Prospective (2015–2017) Community
Mean ± SD
8.5 ± 1.7
60% Unknown Unknown HST
Rybczynski et al. Germany (2010) 68 adults
30.88% OSA 
(mild in 21% 
and moderate in 
7.35%, severe 
2.95%)
Prospective Community/ MFS clinic
Mean ± SD 
(range) 41 ± 14 
(18–70)
51.47% 22 ± 4 Unknown HST
Sowho et al. United States (2018) 49 adults 69% Prospective
Community 
(through the 
annual Marfan 
Foundation)
Mean ± SD
51.8 ± 13.4
57.14% 27.2 ± 6.3 Unknown HST
AHI = apnea-hypopnea index, BMI = body mass index, HST = home sleep test (in-home), MFS = Marfan syndrome, OSA = obstructive sleep apnea (AHI at 
least 1 event/h in children and adolescents and more than 5 events/h in those older than 18 years), PSG = polysomnography (in-laboratory), SD = standard 
deviation, SDB = sleep-disordered breathing (includes primary snoring, UARS, and OSA), UARS = upper airway resistance syndrome.
Figure 1—Prevalence rate of OSA among EDS population.
Event rate is the percentage of OSA in the group, with overall event rate of 0.39 or 39%. Lower limit versus upper limit is range where prevalence of OSA 
in EDS would occur. P value is whether this relationship occur by chance or not. CI = confidence interval, EDS = Ehlers-Danlos syndrome, LL = lower limit, 
OSA = obstructive sleep apnea, UL = upper limit.
Figure 2—Prevalence rate of OSA among MFS population.
Event rate is the percentage of OSA in the group, with overall event rate of 0.597 or 60%. Lower limit versus upper limit is range where prevalence of 
OSA in EDS would occur. P value is whether this relationship occur by chance or not. CI = confidence interval, LL = lower limit, MFS = Marfan syndrome, 
OSA = obstructive sleep apnea, UL = upper limit.
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47.8–88.2). In contrast, the prevalence rate (57.3% [35.3–76.7]) 
was lower among the five adult studies (n = 218).
Referral Source and OSA Prevalence
One would expect a higher prevalence of OSA to be reported 
among individuals presenting at a sleep clinic compared to 
those from community settings or clinics specializing in hy-
permobility disorders. Accordingly, we examined the effects of 
excluding individuals with EDS or MFS who may have been 
recruited from a sleep clinic on OSA prevalence rates. Three 
studies among the EDS group were unclear as to whether their 
sample was from a sleep clinic or another setting. Among the 
three studies that clearly were not from sleep clinics (in addition 
to the unpublished study),10,15,17 OSA prevalence ranged from 
32.0% to 42.0% (average prevalence rate = 32.3%; P < .001), 
somewhat lower than the rate reported when including all stud-
ies, but still much higher than in general community samples 
of individuals without EDS. A more variable prevalence, rang-
ing from 26.0% to 100%, was found among the three remaining 
studies that potentially included individuals from sleep clinics 
(average prevalence rate = 70.6%; P = .40).13,14,16 In contrast, each 
study of individuals with MFS appears to have evaluated them 
from community or other samples that did not include sleep clin-
ics, thus minimizing concerns about selection bias of the MFS 
samples in estimating OSA prevalence.
Study Country and OSA Prevalence
Of note, among the included studies in the EDS group, three 
were from the United States (n = 596, 65 and 27 across the three 
studies), three from Switzerland (n = 100, 24 and 29) and one 
from France (n = 34). Those from the United States had a prev-
alence ranging from 26% to 70%, whereas those from Swit-
zerland ranged from 27% to 42%, whereas the one study from 
France reported 100% OSA prevalence. This latter study had a 
modest sample size (n = 34) and, perhaps more importantly, was 
performed with patients with EDS who were referred to a sleep 
clinic, which likely explains the exceptionally high prevalence 
of OSA in their sample. More broadly, the different prevalence 
rates of OSA across countries may be related to the use of dif-
ferent scoring systems across countries. In the MFS group, two 
studies were from Australia (n = 25 and 15), and one each from 
Italy (n = 20), Germany (n = 68), Switzerland (n = 61), and the 
United States (n = 49). Italy, the United States, and Australia 
had the highest prevalence, ranging from 70% to 86%, com-
pared to the other countries where prevalence was 21% to 34%.
OSA Severity
Analyzing the severity of OSA in EDS, based on one study 
including 100 adult individuals, 21% had mild (AHI 5 to < 15 
events/h), 11% moderate (AHI 15 to < 30 events/h), and 4% 
severe (AHI ≥ 30 events/h) OSA.15 Among adults with MFS, 
three studies showed mild OSA occurring in 15% to 28% of in-
dividuals as categorized by AHI cutoffs ranging from 5 to < 15 
events/h, whereas 7% to 20% of individuals exhibiting mod-
erate OSA (AHI 16 to < 30 events/h) and 3% to 16% of indi-
viduals exhibiting severe OSA (AHI ≥ 30 events/h) in 3% to 
16%.25,26,30 Among 25 individuals with MFS, 28% (n = 7) had 
mild OSA, 20% (n = 9) had moderate OSA, and 16% (n = 4) had 
severe OSA.30 In another study by Rybczynski and colleagues 
that included 68 individuals with MFS, 21% (n = 14) had mild 
OSA, 7% (n = 5) moderate OSA, and 3% (n = 2) had severe 
OSA.25 In the third study by Kohler et al. that included 61 indi-
viduals with MFS, 15% (n = 9) had mild OSA, 11% (n = 7) had 
moderate OSA, and 6.5% (n = 4) had severe OSA.26
OSA Prevalence in EDS and MFS 
Compared to Controls
There were four studies, two in each group, that compared the 
prevalence of OSA to control patients without a hypermobil-
ity disorder (Table 1 and Figure 3). An OR of 6.28 (95% CI 
3.31–11.93, P < .001, Z = 5.61) was found, suggesting that indi-
viduals with EDS or MFS are six times more likely than those 
without a hypermobility disorder to have OSA. The Q value 
in these studies was 1.85 and I 2 < 0.0001. In the two studies of 
individuals with EDS, the OR was 6.52 (P < .0001, Z = 4.72, Q 
value = 0.23 and I 2 < 0.0001). Similarly, in the two studies of 
individuals with MFS, the OR was 6.70 (P = .016, Z = 2.42 and 
Q value = 1.59 and I 2 = 36.95).
DISCUSSION
Although the prevalence of OSA in both EDS and MFS varied 
among studies, a consistently high prevalence (ranging between 
Figure 3—Combined comparison of EDS and MFS versus controls.
Odds ratio is the increased probability of OSA occurring in EDS/MFS individuals versus controls, an odds ratio of 6.28 is noticed. Lower limit versus 
upper limit is range where prevalence of OSA in EDS would occur. P value is whether this relationship occur by chance or not. CI = confidence interval, 
EDS = Ehlers-Danlos syndrome, LL = lower limit, MFS = Marfan syndrome, OSA = obstructive sleep apnea, UL = upper limit.
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26% and 100%) was found compared to the rates typically re-
ported for community samples. The estimated prevalence of 
OSA in community samples typically ranges from 0.7% to 
3.3%, although a recent systematic review suggested a higher 
range from 9% to 38% among adults using an AHI cutoff of 
5 events/h,31–34 still lower than rates found for EDS and MFS 
in our analysis. Overall, we found prevalence rates of 39.4% 
and 59.7% for EDS and MFS, respectively. Although a higher 
prevalence of OSA was found in EDS population referred to 
the sleep clinic versus the community sample (70.6 versus 
32.3 respectively), they were both elevated. Such elevated rates 
highlight the importance of evaluating OSA in these two popu-
lations of individuals with a hypermobility disorder.
In general community samples, males and obese individuals 
have elevated risk for OSA. Although not examined in most 
studies, one study did report that individuals with obesity and 
males with OSA were at increased risk for OSA than either 
nonobese and female individuals with EDS, consistent with 
community samples.15 This finding supports a significant role 
of classical risk factors in the EDS population. Examining 
child studies, some evidence of possible moderation was found 
as higher rates of OSA were found among adults than children, 
but this finding needs to be tempered by the very modest sam-
ple size of the one study examining both age groups, as well as 
the presence of different AHI cutoffs for children.30 In contrast, 
the prevalence of OSA appears to be very similar among chil-
dren and adults with EDS based on the limited data.
There are several potential causes for these high rates of 
OSA among individuals with hypermobility disorders. First, 
the abnormal collagen quality that is present in the airway 
leads to increased nasal airway resistance and collapse. Pa-
tients with both disorders have chest (pectus) as well as spinal 
cord (ie, scoliosis and kyphosis) deformities have increased 
OSA prevalence. In addition, there is evidence that craniofacial 
abnormalities (high-arched palate and mandibular retrogna-
thia) might contribute to high OSA prevalence in patients with 
MFS.26 This is in contrast to individuals with EDS, for whom 
craniofacial phenotyping (based on a computer algorithm, 
which is usually used in risk stratification for OSA patients in 
sleep clinics) has been found to indicate no abnormalities when 
compared to the general population.15,35 Regarding OSA risk 
due to obesity, people with MFS are usually tall and slim. One 
study suggested that the effect of the hypermobility syndrome 
is comparable to a +11 kg/m2 BMI gain in the normal popula-
tion15. Lung abnormalities, including higher prevalence of si-
nusitis, tracheomegaly and increased gas transfer coefficient 
have also been observed in EDS population.36
There were two studies comparing age- and sex-matched pa-
tients with EDS and control patients, both conducted in Swit-
zerland by the same group. In the child and adolescent sample, 
OSA prevalence was found to be 43% compared to the control 
group at 13%. In the adult-based study, the prevalence of OSA 
in the EDS group was 32% compared to 6% in the comparison 
group. These rates are lower than the overall prevalence found 
in our meta-analysis, possibly due to the small number of indi-
viduals enrolled in the study (24 in the children and adolescent 
study versus 100 in the adult group), but further support the 
conclusion that individuals with hypermobility disorders are at 
increased risk of OSA. Although there was a higher prevalence 
of OSA in the child group compared to adults, it is not clear 
if the larger airway might decrease the prevalence. EDS has 
13 different subtypes; although the prevalence of OSA among 
different subtypes are not well studied, one study examined 
prevalence among classic, vascular, hypermobility, and other 
subtypes and found no difference in prevalence or mean AHI 
(11% among classical and vascular subtypes and 14% among 
each of the hypermobility and unknown types).14 Similarly, two 
studies were found to include individuals with MFS: a study 
involving 25 children found a prevalence of 64.0% versus 8.3% 
in the control group including 12 counterparts.24 Similarly, the 
prevalence of OSA in adults with MFS showed a rate of 32.8% 
versus 11.5% in controls (61 were in MFS group versus 26 con-
trols).26 However, these studies were less well controlled com-
pared to the EDS studies. Constriction of the maxillary arch 
(high arched palate) and increased nasal airway resistance was 
found in the MFS group compared to the control groups.22–24
The high prevalence of OSA in patients with hypermobility 
may contribute to significant adverse health outcomes in this 
population. Patients with MFS and EDS already report lower 
levels of quality of life and higher rates of excessive daytime 
sleepiness when compared to the general population.8,15 OSA 
is a well-known underlying cause of impaired quality of life, 
fatigue, and daytime sleepiness and in one study the OSA se-
verity was positively associated with lower quality of life.15 In 
addition, several studies suggested a higher prevalence of car-
diovascular complications in untreated patients with OSA.37–39 
This is especially applicable in patients with MFS in which 
suggested higher rate of aortic dissection with higher AHI,37 
faster aortic artery dilatation expansion rate in those with high 
oxygen desaturation index above 30 events/h compared to 
those with lower levels38 and decreased progression of aortic 
root dilatation with the use of continuous positive airway pres-
sure to treat the associated OSA.39 This is probably related to 
the sympathetic hyperactivity and increased arousal caused by 
OSA increasing blood pressure, leading to increased shearing 
effect on vessels and endothelial dysfunction.40 Similar mecha-
nisms and observations have been observed in the general 
population.41
Studies examining the sensitivity and specificity of home 
sleep studies versus in-laboratory studies suggest the latter 
should be used in the EDS and MFS populations to most ac-
curately detect OSA cases.10 This is in comparison with the 
general adult population in which in-home sleep studies are 
usually recommended. A four-fold increase in OSA diagnos-
tic sensitivity was found with in-laboratory compared to in-
home testing in one study.11 These authors found an unusually 
high number of inconclusive results from in-home testing (71 
inconclusive cases out of 123 who have in-home studies, or 
58%). Given the high number of inconclusive cases who had to 
repeat the study as well as still-suspected cases of OSA among 
those who tested negative for OSA (ie, possible false nega-
tives) lead clinicians to frequently order in-laboratory studies 
after already conducting in-home studies.11 Thus, conducting 
the initial tests in-laboratory rather than in-home can lead to a 
quicker time to diagnosis, as well as avoiding a possible high 
dropout rate for those patients who are asked to complete two 
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different types of sleep studies. The exceptionally high sensi-
tivity rate with the in-laboratory testing might be explained by 
the high pulmonary and cardiovascular complications found 
among those with hypermobility syndromes. Previous stud-
ies have recommended the use of in-laboratory testing rather 
than in-home testing for individuals with pulmonary, neuro-
muscular disease or cardiovascular complications in the gen-
eral population (ie, without hypermobility syndrome) due to 
its increased diagnostic accuracy among these populations.42 
Moreover, in the adult population without hypermobility syn-
drome, untreated OSA has been associated with a variety of 
medical conditions including obesity, hypertension, diabetes 
mellitus, and strokes. Although it is less studied in hypermo-
bility syndrome, some studies suggest a worsening of vascular 
abnormalities in the MFS group, thus highlighting the impor-
tance of accurately diagnosing and treating this condition.37–39
The current review and meta-analysis has several limita-
tions. First, the identified studies generally include a small 
number of participants, which may in part explain the high de-
gree of variability in OSA prevalence rates across some stud-
ies. In addition, most studies did not examine the subtypes of 
the disorders or presence of other craniofacial measurements 
that can significantly affect the prevalence. Second, selection 
bias was not clearly delineated in some studies. Nonetheless, 
even when excluding studies that appear to have used sleep 
clinic populations, the prevalence of OSA was still very high 
among those with EDS and MFS. Third, due to the rarity of 
other hypermobility syndrome cases, we could not find suf-
ficient research assessing the prevalence in these disorders (eg, 
pseudoxanthoma elasticum, cutis laxa syndrome, ectopia lentis 
syndrome, Weill-Marchesani syndrome, and Shprintzen-Gold-
berg syndrome). Fourth, these studies assess a point prevalence 
of the disorder; it is not clear whether OSA develops early in 
the disease (ie, during childhood), with the narrow airway 
compared to adults worsening the condition or the possibility 
that time and strain over the abnormal collagen would lead to 
worsening of OSA with age. Although the latter might be more 
expected and substantiated by the higher prevalence of OSA in 
the adult group compared to child with EDS (in children, prev-
alence ranged from 26% to 42% compared to adults ranging 
from 42% to 100%), this did not appear to be the case for MFS 
(children prevalence was 80% compared to the adults at 31% to 
69%). However, the small sample size and selection bias makes 
it difficult to draw any conclusions. In addition, it is not clear 
if upper airway exercise might affect the OSA prevalence in 
this population. This contradicts with the results from a study 
conducted by Rybczynski et al., in which older age and high 
BMI were associated with higher AHI.25 Fifth, the definition 
and criteria for an OSA diagnosis has varied over the years: 
although most studies have used an AHI of 5 events/h as a 
cutoff, others have also included oxygen desaturation index as 
a measure, thus possibly underestimating the prevalence. Last, 
this study focused on OSA and did not access for central ap-
neas nor upper airway resistance syndrome (UARS). In a study 
conducted by Rybczynski et al., half of the MFS events were 
central apneas rather than obstructive events.25 In the study by 
Bobcock et al., for example, they assessed for UARS and found 
59 individuals or 9.9% to have the disorder. Primary snoring 
occurred in 27 individuals representing 4.5%.10
Although there is clearly a higher prevalence of OSA among 
patients with hypermobility syndrome, more controlled studies 
are needed. The use of standardized polysomnography mea-
sures and grading as well as detailed assessment of craniofa-
cial, chest, and subtype of the disorder should be conducted. 
Longitudinal studies following individuals with hypermobility 
syndrome from an early age would be helpful in better iden-
tifying the developmental course of OSA in this population, 
including typical ages of onset. Given the low prevalence of 
EDS and MFS, multisite studies that pool data across individu-
als are needed to better identify potential risk factors for OSA 
among individuals with hypermobility disorders. Clinicians in 
the care of patients with hypermobility syndrome should spe-
cifically ask for OSA-related symptoms (eg, fatigue, daytime 
sleepiness, etc.), even when the patient does not have obesity 
and other known risk factors are not present. It remains con-
troversial as to whether there is a need of performing polysom-
nography in this population as a standard of practice for all 
cases, even with the lack of OSA signs and symptoms. This is 
especially significant given the lack of self-reported measures 
such as EDS not being related to OSA presence or its sever-
ity.25 In addition, although home sleep studies are increasingly 
used for adults, such studies could miss a significant number of 
OSA cases among the hypermobility group.10 Highlighting and 
monitoring compliance to the treatment of OSA to individuals 
in whom hypermobility syndrome has been diagnosed appear 
to be essential in this population and might prevent fatal car-
diovascular complications.
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